Longevity Today
Sign In

All Articles

21 articles

All TopicsCancerHeart DiseaseAlzheimer'sParkinson'sDiabetesGut HealthNutritionStrength & FitnessSupplements & PeptidesStem CellsReversing AgingAuto-ImmunityAdvanced TherapiesSleep & Mindfulness
📋All Types🔬Papers📖Reviews▶️Videos🎙️Podcasts🧪Trials💊Approvals📰Press Releases📚Tutorials🎬Animations
FDA Approves Keytruda Combo for Platinum-Resistant Ovarian Cancer
Cancer Research

FDA Approves Keytruda Combo for Platinum-Resistant Ovarian Cancer

Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.

Drug Approval
Apr 20, 2026 0
FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win
Cancer Research

FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win

Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.

Drug Approval
Apr 20, 2026 0
FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program
Metabolic Health

FDA Fast-Tracks New Weight Loss Drug Foundayo Under Priority Program

Orforglipron approved 294 days ahead of schedule for obesity treatment, marking first drug under new priority voucher system.

Drug Approval
Apr 16, 2026 0
FDA Approves First Drug for Hunter Syndrome Brain Complications in Children
Brain Health

FDA Approves First Drug for Hunter Syndrome Brain Complications in Children

Avlayah becomes the first treatment targeting neurologic symptoms of rare genetic disorder affecting 500 Americans.

Drug Approval
Apr 15, 2026 0
FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026
Cancer Research

FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026

New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.

Drug Approval
Apr 15, 2026 0
FDA Approves First Treatments for Rare Neurological Conditions
Brain Health

FDA Approves First Treatments for Rare Neurological Conditions

Two breakthrough approvals target Hunter syndrome brain complications and cerebral folate deficiency for the first time.

Drug Approval
Apr 7, 2026 0
FDA Approves Foundayo for Weight Loss in Record 50 Days
Metabolic Health

FDA Approves Foundayo for Weight Loss in Record 50 Days

New GLP-1 drug Foundayo gets fastest FDA approval since 2002, targeting obesity and metabolic health through appetite control.

Drug Approval
Apr 6, 2026 0
FDA Approves Two New Weight Loss Drugs in Record Two-Week Span
Metabolic Health

FDA Approves Two New Weight Loss Drugs in Record Two-Week Span

Foundayo and Zepbound receive rapid FDA approval for chronic weight management in adults with obesity or weight-related conditions.

Drug Approval
Apr 5, 2026 0
FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity
Metabolic Health

FDA Approves Two New Weight Loss Drugs Foundayo and Zepbound for Obesity

FDA approves Foundayo (orforglipron) and Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight conditions.

Drug Approval
Apr 4, 2026 0
PreviousPage 2 of 2